As of 2024-07-27, the EV/EBITDA ratio of Sarepta Therapeutics Inc (SRPT) is 15,334.95. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRPT's latest enterprise value is 14,445.52 mil USD. SRPT's TTM EBITDA according to its financial statements is 0.94 mil USD. Dividing these 2 quantities gives us the above SRPT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the low predictability of business.
| Range | Selected | |
| Trailing P/E multiples | 18.3x - 39.3x | 23.6x |
| Forward P/E multiples | 21.9x - 34.7x | 27.8x |
| Fair Price | (8.41) - (8.20) | (8.33) |
| Upside | -105.8% - -105.7% | -105.8% |
| Date | EV/EBITDA |
| 2024-07-26 | 15,334.95 |
| 2024-07-25 | 15,668.08 |
| 2024-07-24 | 15,511.55 |
| 2024-07-23 | 15,676.10 |
| 2024-07-22 | 15,546.66 |
| 2024-07-19 | 15,472.41 |
| 2024-07-18 | 15,288.79 |
| 2024-07-17 | 15,601.85 |
| 2024-07-16 | 15,810.56 |
| 2024-07-15 | 16,180.81 |
| 2024-07-12 | 16,124.62 |
| 2024-07-11 | 16,124.62 |
| 2024-07-10 | 15,837.65 |
| 2024-07-09 | 15,937.99 |
| 2024-07-08 | 16,060.91 |
| 2024-07-05 | 16,086.49 |
| 2024-07-03 | 16,224.96 |
| 2024-07-02 | 16,334.33 |
| 2024-07-01 | 16,590.20 |
| 2024-06-28 | 16,715.62 |
| 2024-06-27 | 16,711.61 |
| 2024-06-26 | 16,606.25 |
| 2024-06-25 | 16,721.64 |
| 2024-06-24 | 17,302.61 |
| 2024-06-21 | 16,988.55 |
| 2024-06-20 | 13,253.90 |
| 2024-06-18 | 12,653.87 |
| 2024-06-17 | 12,584.64 |
| 2024-06-14 | 13,187.68 |
| 2024-06-13 | 13,404.41 |
| 2024-06-12 | 12,900.71 |
| 2024-06-11 | 13,041.18 |
| 2024-06-10 | 13,162.59 |
| 2024-06-07 | 13,235.84 |
| 2024-06-06 | 12,645.84 |
| 2024-06-05 | 12,881.64 |
| 2024-06-04 | 12,874.62 |
| 2024-06-03 | 13,327.15 |
| 2024-05-31 | 13,892.06 |
| 2024-05-30 | 13,349.23 |
| 2024-05-29 | 12,526.44 |
| 2024-05-28 | 12,233.45 |
| 2024-05-24 | 13,249.89 |
| 2024-05-23 | 13,618.14 |
| 2024-05-22 | 13,735.53 |
| 2024-05-21 | 13,817.81 |
| 2024-05-20 | 13,989.39 |
| 2024-05-17 | 14,044.58 |
| 2024-05-16 | 14,181.04 |
| 2024-05-15 | 14,156.96 |